Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Retatrutide may be especially promising for: Patients who have struggled to lose weight despite GLP-1 therapy Individuals with obesity complicated by diabetes, fatty liver, or cardiovascular risk factors Patients seeking a more comprehensive metabolic reset rather than just weight reduction Safety & Current Status It's important to know: Retatrutide is not yet FDA-approved and is currently available only through clinical research and select specialty clinics
Why It's Not GLP-1 (And Why That Matters) Drugs like semaglutide and tirzepatide work mostly by suppressing appetite
doi: 10.1016/j.diabres.2015.07.015 4 SunFWuSWangJGuoSChaiSYangZet al
Preclinical data from Eli Lilly's retatrutide characterization work indicate that hepatic triglyceride content fell 81.1% from baseline at 48 weeks in patients receiving 12 mg
Mid-dose program (144 mg total) With 144 mg across three months, the mid-dose program supports a higher weekly dose
Patients are expected to regain weight they lost if they stop using the medication
US$ 21.24
US$ 22.83
US$ 24.62
US$ 28.34
US$ 26.20
US$ 27.00
US$ 24.17
US$ 27.14
